GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Cisatracurium - NIMBEX intravenous injection

NIMBEX / cisatracurium

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Preserved recovery does not imply identical onset or metabolite exposure

The source describes slower ESRD onset and longer metabolite half-lives despite similar recovery.

Before applying: Preserve neuromuscular monitoring and anesthetic context. Do not convert a PK study dose into a universal intubating dose.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - NIMBEX

Product / population
NIMBEX IV neuromuscular blocker in a monitored anesthetic/critical-care setting; not a sedative or analgesic substitute.
Renal measure
ESRD and renal PK/PD; no new renal-dose calculation

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Before using this finding

Separate onset and metabolite accumulation from recovery duration.

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Renal dosing, restrictions and evidence limits

In the selected ESRD study, recovery after a 0.1 mg/kg study dose was not clinically altered, but onset of blockade was slower. The mirror advises considering at least one additional minute between administration and attempted intubation, with peripheral nerve-stimulator assessment of adequacy and subsequent dosing.

Predominantly organ-independent parent-drug elimination does not eliminate all renal considerations: metabolite half-lives are longer in ESRD and concentrations may rise during prolonged administration. This study dose is not a universal recommended intubating dose, and the selected evidence does not establish a dialysis supplement.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/nimbex-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

GlobalRPh RX List - NIMBEX

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - NIMBEX

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding

Separate onset and metabolite accumulation from recovery duration.

Dialysis evidence: No dialysis regimen established in selected content

NIMBEX IV neuromuscular blocker in a monitored anesthetic/critical-care setting; not a sedative or analgesic substitute.

Renal method: ESRD and renal PK/PD; no new renal-dose calculation
Retrieved: 2026-09-10

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

pk pd and metabolite distinction

Preserved recovery does not imply identical onset or metabolite exposure

The source describes slower ESRD onset and longer metabolite half-lives despite similar recovery.

How to use this: Preserve neuromuscular monitoring and anesthetic context. Do not convert a PK study dose into a universal intubating dose.

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/nimbex-drug/

Exact product and population

NIMBEX IV neuromuscular blocker in a monitored anesthetic/critical-care setting; not a sedative or analgesic substitute.

RDM59-SCOPE-cisatracurium-nimbex · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - NIMBEX

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · NIMBEX IV neuromuscular blocker in a monitored anesthetic/critical-care setting; not a sedative or analgesic substitute.

Renal method: ESRD and renal PK/PD; no new renal-dose calculation
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding

Separate onset and metabolite accumulation from recovery duration.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

In the selected ESRD study, recovery after a 0.1 mg/kg study dose was not clinically altered, but onset of blockade was slower. The mirror advises considering at least one additional minute between administration and attempted intubation, with peripheral nerve-stimulator assessment of adequacy and subsequent dosing.

Predominantly organ-independent parent-drug elimination does not eliminate all renal considerations: metabolite half-lives are longer in ESRD and concentrations may rise during prolonged administration. This study dose is not a universal recommended intubating dose, and the selected evidence does not establish a dialysis supplement.

RDM59-rxlist-cisatracurium-nimbex-bd94967651-C1 · Source locator: Dosage: Geriatric/ESRD; Renal Impairment; Clinical Pharmacology: renal PK

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/nimbex-drug/
Retrieved
2026-09-10
Renal-function method
ESRD and renal PK/PD; no new renal-dose calculation
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
e8c5dda9ab2056e9721b8d9b827811d9208cb27f2c7828adc176235f92d97c04

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/nimbex-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
fe5bf34bdf9b9411ed7c86709ce5484628f6a6b9d23c9d226cce0433bd130cf4
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report